Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meina Liang

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
Journal of Pharmaceutical Sciences|October 24, 2012
Pharmacokinetic and pharmacodynamic comparability study of moxetumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeysBing Wang, Meina Liang, Zhenling Yao, et al.
Assay and Drug Development Technologies|October 18, 2007
Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platformsMeina Liang, Scott L Klakamp, Cherryl Funelas, et al.
British Journal of Clinical Pharmacology|February 21, 2020
Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemiaDenison Kuruvilla, Yen Lin Chia, Kemal Balic, et al.
Antibodies (Basel, Switzerland)|October 24, 2023
Multiplex Bioanalytical Methods for Comprehensive Characterization and Quantification of the Unique Complementarity-Determining-Region Deamidation of MEDI7247, an Anti-ASCT2 Pyrrolobenzodiazepine Antibody-Drug ConjugateYue Huang, Jiaqi Yuan, Ruipeng Mu, et al.
Molecular Pharmacology|October 14, 2005
Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8Christopher A Haskell, Richard Horuk, Meina Liang, et al.
Molecular Cancer Therapeutics|May 28, 2021
First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric CancerMark D Pegram, Erika P Hamilton, Antoinette R Tan, et al.
Blood|October 7, 2017
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemiaAlan S Wayne, Nirali N Shah, Deepa Bhojwani, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|October 19, 2016
Development of a new ARCHITECT automated periostin immunoassayNicolette M Jeanblanc, Philip M Hemken, Maria J Datwyler, et al.
The Journal of Biological Chemistry|July 14, 2006
Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validationNagarajan Vaidehi, Sabine Schlyer, Rene J Trabanino, et al.
Lupus Science & Medicine|April 13, 2018
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosusJeffrey M Riggs, Richard N Hanna, Bhargavi Rajan, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Journal of Pharmaceutical Sciences|October 24, 2012
Pharmacokinetic and pharmacodynamic comparability study of moxetumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeysBing Wang, Meina Liang, Zhenling Yao, et al.
Assay and Drug Development Technologies|October 18, 2007
Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platformsMeina Liang, Scott L Klakamp, Cherryl Funelas, et al.
British Journal of Clinical Pharmacology|February 21, 2020
Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemiaDenison Kuruvilla, Yen Lin Chia, Kemal Balic, et al.
Antibodies (Basel, Switzerland)|October 24, 2023
Multiplex Bioanalytical Methods for Comprehensive Characterization and Quantification of the Unique Complementarity-Determining-Region Deamidation of MEDI7247, an Anti-ASCT2 Pyrrolobenzodiazepine Antibody-Drug ConjugateYue Huang, Jiaqi Yuan, Ruipeng Mu, et al.
Molecular Pharmacology|October 14, 2005
Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8Christopher A Haskell, Richard Horuk, Meina Liang, et al.
Molecular Cancer Therapeutics|May 28, 2021
First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric CancerMark D Pegram, Erika P Hamilton, Antoinette R Tan, et al.
Blood|October 7, 2017
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemiaAlan S Wayne, Nirali N Shah, Deepa Bhojwani, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|October 19, 2016
Development of a new ARCHITECT automated periostin immunoassayNicolette M Jeanblanc, Philip M Hemken, Maria J Datwyler, et al.
The Journal of Biological Chemistry|July 14, 2006
Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validationNagarajan Vaidehi, Sabine Schlyer, Rene J Trabanino, et al.
Lupus Science & Medicine|April 13, 2018
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosusJeffrey M Riggs, Richard N Hanna, Bhargavi Rajan, et al.
Pageof 8